Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 3	2026-07-14		NCT02032823

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AstraZeneca	806
Frontier Science & Technology Research Foundation, Inc.	9
Merck Sharp & Dohme LLC	650
Myriad Genetic Laboratories, Inc.	5
NRG Oncology	93
The Breast Adjuvant Study Team	1

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.